Terminated PHASE3 INTERVENTIONAL 4-arm NCT00294723

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c (LEAD-3)

Liraglutide Effect and Action in Diabetes (LEAD-3): Effect on Glycemic Control of Liraglutide Versus Glimepiride in Type 2 Diabetes

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 2

Interventions glimepiride liraglutide placebo

Updated 12 times since 2017 Last updated: Jan 24, 2017 Started: Feb 28, 2006 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power

Other terminated trials from Novo Nordisk A/S

See all terminations from Novo Nordisk A/S

Other Diabetes trials with similar outcome

Browse all Diabetes trials

This PHASE3 trial investigates Diabetes and Diabetes Mellitus, Type 2 and is currently terminated or withdrawn. Novo Nordisk A/S leads this study, which shows 12 recorded versions since 2006 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 7 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE3
May 2017 — Aug 2017 [monthly]

Terminated PHASE3
Feb 2017 — May 2017 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Arlington, United States , Asheville, United States , Athens, United States , Atlanta, United States , Baltimore, United States , Bend, United States , Berlin, United States , Blue Ridge, United States , Butte, United States and 88 more locations